» Articles » PMID: 30790217

Age-Related Reduction in Cortical Thickness in First-Episode Treatment-Naïve Patients with Schizophrenia

Overview
Journal Neurosci Bull
Specialty Neurology
Date 2019 Feb 22
PMID 30790217
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Substantial evidence supports the neurodevelopmental hypothesis of schizophrenia. Meanwhile, progressive neurodegenerative processes have also been reported, leading to the hypothesis that neurodegeneration is a characteristic component in the neuropathology of schizophrenia. However, a major challenge for the neurodegenerative hypothesis is that antipsychotic drugs used by patients have profound impact on brain structures. To clarify this potential confounding factor, we measured the cortical thickness across the whole brain using high-resolution T1-weighted magnetic resonance imaging in 145 first-episode and treatment-naïve patients with schizophrenia and 147 healthy controls. The results showed that, in the patient group, the frontal, temporal, parietal, and cingulate gyri displayed a significant age-related reduction of cortical thickness. In the control group, age-related cortical thickness reduction was mostly located in the frontal, temporal, and cingulate gyri, albeit to a lesser extent. Importantly, relative to healthy controls, patients exhibited a significantly smaller age-related cortical thickness in the anterior cingulate, inferior temporal, and insular gyri in the right hemisphere. These results provide evidence supporting the existence of neurodegenerative processes in schizophrenia and suggest that these processes already occur in the early stage of the illness.

Citing Articles

Cortical and Subcortical Structural Morphometric Profiles in Individuals with Nonaffective and Affective Early Illness Psychosis.

Hua J, Mathalon D Schizophr Bull Open. 2024; 3(1):sgac028.

PMID: 39144757 PMC: 11206002. DOI: 10.1093/schizbullopen/sgac028.


Brain Age Gap in Early Illness Schizophrenia and the Clinical High-Risk Syndrome: Associations With Experiential Negative Symptoms and Conversion to Psychosis.

Hua J, Abram S, Loewy R, Stuart B, Fryer S, Vinogradov S Schizophr Bull. 2024; 50(5):1159-1170.

PMID: 38815987 PMC: 11349027. DOI: 10.1093/schbul/sbae074.


A multicentre study on grey matter morphometric biomarkers for classifying early schizophrenia and parkinson's disease psychosis.

Knolle F, Arumugham S, Barker R, Chee M, Justicia A, Kamble N NPJ Parkinsons Dis. 2023; 9(1):87.

PMID: 37291143 PMC: 10250419. DOI: 10.1038/s41531-023-00522-z.


Cortical and subcortical brain morphometry abnormalities in youth at clinical high-risk for psychosis and individuals with early illness schizophrenia.

Hua J, Loewy R, Stuart B, Fryer S, Niendam T, Carter C Psychiatry Res Neuroimaging. 2023; 332:111653.

PMID: 37121090 PMC: 10362971. DOI: 10.1016/j.pscychresns.2023.111653.


Brain-wide and cell-specific transcriptomic insights into MRI-derived cortical morphology in macaque monkeys.

Bo T, Li J, Hu G, Zhang G, Wang W, Lv Q Nat Commun. 2023; 14(1):1499.

PMID: 36932104 PMC: 10023667. DOI: 10.1038/s41467-023-37246-w.


References
1.
Lieberman J . Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia. J Clin Psychiatry. 1999; 60 Suppl 12:9-12. View

2.
Lewis D, Pierri J, Volk D, Melchitzky D, Woo T . Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. Biol Psychiatry. 1999; 46(5):616-26. DOI: 10.1016/s0006-3223(99)00061-x. View

3.
Lieberman J . Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry. 1999; 46(6):729-39. DOI: 10.1016/s0006-3223(99)00147-x. View

4.
Keshavan M, Hogarty G . Brain maturational processes and delayed onset in schizophrenia. Dev Psychopathol. 1999; 11(3):525-43. DOI: 10.1017/s0954579499002199. View

5.
Keshavan M . Development, disease and degeneration in schizophrenia: a unitary pathophysiological model. J Psychiatr Res. 2000; 33(6):513-21. DOI: 10.1016/s0022-3956(99)00033-3. View